A manufacturing-focused report described an approach to improve prolonged transfection complex stability for large-scale AAV production, targeting a major upstream bottleneck: adding transfection complex within a narrow time window at scale. The work centers on a transfection complex stabilizer compatible with a transfection reagent workflow and claims to reduce the required complex volume from ~5% to ~2% of total culture volume, while maintaining performance. The goal is to reduce dilution effects, media consumption, and operational risk during scale-up. For AAV developers moving toward broader patient populations, process economics and batch consistency are increasingly decisive as vector supply scales. Any reduction in time sensitivity can translate into lower manufacturing cost, fewer deviations, and more predictable output. The report positions the stabilizer as part of a full workflow designed to support higher titers and capsid quality, a key consideration for downstream fill-finish and clinical comparability.